Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 08:36:35 UTC - HELPFUL

Rated by Participant: 591A64E113BEB3389AEE1C6AC1AB27EC635FAB85C93AB37C2B4D525704EB8A61
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 591A64E113BEB3389AEE1C6AC1AB27EC635FAB85C93AB37C2B4D525704EB8A61
createdAtMillis - 1688891795763
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 1
helpfulEmpathetic - 0
helpfulGoodSources - 0
helpfulUniqueContext - 0
helpfulAddressesClaim - 1
helpfulImportantContext - 1
helpfulUnbiasedLanguage - 1
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 1677803233077522432591A64E113BEB3389AEE1C6AC1AB27EC635FAB85C93AB37C2B4D525704EB8A61